nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilutamide—CYP2C9—Capecitabine—colon cancer	0.171	0.409	CbGbCtD
Nilutamide—CYP2C8—Fluorouracil—colon cancer	0.145	0.348	CbGbCtD
Nilutamide—CYP2C9—Fluorouracil—colon cancer	0.101	0.243	CbGbCtD
Nilutamide—AR—scrotum—colon cancer	0.0633	0.463	CbGeAlD
Nilutamide—Lung disorder—Irinotecan—colon cancer	0.00672	0.0168	CcSEcCtD
Nilutamide—POR—bone marrow—colon cancer	0.00595	0.0435	CbGeAlD
Nilutamide—POR—vagina—colon cancer	0.0057	0.0416	CbGeAlD
Nilutamide—Cough increased—Irinotecan—colon cancer	0.00519	0.013	CcSEcCtD
Nilutamide—Bone pain—Vincristine—colon cancer	0.0051	0.0128	CcSEcCtD
Nilutamide—AR—epithelium—colon cancer	0.00502	0.0366	CbGeAlD
Nilutamide—Interstitial pneumonia—Methotrexate—colon cancer	0.0049	0.0123	CcSEcCtD
Nilutamide—AR—smooth muscle tissue—colon cancer	0.00483	0.0353	CbGeAlD
Nilutamide—POR—liver—colon cancer	0.00481	0.0351	CbGeAlD
Nilutamide—Phosphatase alkaline increased—Irinotecan—colon cancer	0.00475	0.0119	CcSEcCtD
Nilutamide—AR—Regulation of Androgen receptor activity—SPDEF—colon cancer	0.00473	0.111	CbGpPWpGaD
Nilutamide—AR—renal system—colon cancer	0.00465	0.034	CbGeAlD
Nilutamide—Photophobia—Fluorouracil—colon cancer	0.00428	0.0107	CcSEcCtD
Nilutamide—Enzalutamide—ABCB1—colon cancer	0.00419	1	CrCbGaD
Nilutamide—Blood alkaline phosphatase increased—Irinotecan—colon cancer	0.00397	0.00995	CcSEcCtD
Nilutamide—AR—lymphoid tissue—colon cancer	0.00386	0.0282	CbGeAlD
Nilutamide—AR—digestive system—colon cancer	0.00382	0.0279	CbGeAlD
Nilutamide—CYP2C8—renal system—colon cancer	0.00376	0.0275	CbGeAlD
Nilutamide—POR—lymph node—colon cancer	0.00369	0.0269	CbGeAlD
Nilutamide—Visual disturbance—Irinotecan—colon cancer	0.00364	0.00913	CcSEcCtD
Nilutamide—CYP2C19—digestive system—colon cancer	0.00354	0.0258	CbGeAlD
Nilutamide—Gastrointestinal haemorrhage—Irinotecan—colon cancer	0.00345	0.00865	CcSEcCtD
Nilutamide—Nocturia—Capecitabine—colon cancer	0.00343	0.0086	CcSEcCtD
Nilutamide—Cardiac failure—Fluorouracil—colon cancer	0.00339	0.00849	CcSEcCtD
Nilutamide—AR—vagina—colon cancer	0.00337	0.0246	CbGeAlD
Nilutamide—Lung disorder—Methotrexate—colon cancer	0.00335	0.00839	CcSEcCtD
Nilutamide—Interstitial lung disease—Methotrexate—colon cancer	0.00335	0.00839	CcSEcCtD
Nilutamide—Cataract—Capecitabine—colon cancer	0.00334	0.00838	CcSEcCtD
Nilutamide—Bone pain—Capecitabine—colon cancer	0.00332	0.00833	CcSEcCtD
Nilutamide—Gastrointestinal haemorrhage—Fluorouracil—colon cancer	0.00331	0.00829	CcSEcCtD
Nilutamide—Blood creatinine increased—Irinotecan—colon cancer	0.00323	0.00811	CcSEcCtD
Nilutamide—Aspartate aminotransferase increased—Vincristine—colon cancer	0.00319	0.008	CcSEcCtD
Nilutamide—Phosphatase alkaline increased—Capecitabine—colon cancer	0.00318	0.00798	CcSEcCtD
Nilutamide—CYP2C19—vagina—colon cancer	0.00312	0.0228	CbGeAlD
Nilutamide—Melaena—Capecitabine—colon cancer	0.00311	0.00779	CcSEcCtD
Nilutamide—Aspartate aminotransferase increased—Irinotecan—colon cancer	0.00311	0.00779	CcSEcCtD
Nilutamide—Dry skin—Fluorouracil—colon cancer	0.00303	0.0076	CcSEcCtD
Nilutamide—Angina pectoris—Irinotecan—colon cancer	0.00291	0.00729	CcSEcCtD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CDX1—colon cancer	0.0029	0.0679	CbGpPWpGaD
Nilutamide—AR—liver—colon cancer	0.00284	0.0208	CbGeAlD
Nilutamide—Erectile dysfunction—Vincristine—colon cancer	0.00282	0.00707	CcSEcCtD
Nilutamide—Angina pectoris—Fluorouracil—colon cancer	0.00278	0.00698	CcSEcCtD
Nilutamide—Abnormal vision—Capecitabine—colon cancer	0.00278	0.00696	CcSEcCtD
Nilutamide—Upper respiratory tract infection—Irinotecan—colon cancer	0.00277	0.00695	CcSEcCtD
Nilutamide—Weight decreased—Vincristine—colon cancer	0.00277	0.00695	CcSEcCtD
Nilutamide—Pneumonia—Vincristine—colon cancer	0.00275	0.00689	CcSEcCtD
Nilutamide—CYP2C9—digestive system—colon cancer	0.00274	0.02	CbGeAlD
Nilutamide—CYP2C8—vagina—colon cancer	0.00272	0.0199	CbGeAlD
Nilutamide—Depression—Vincristine—colon cancer	0.00272	0.00683	CcSEcCtD
Nilutamide—Weight decreased—Irinotecan—colon cancer	0.0027	0.00677	CcSEcCtD
Nilutamide—Pneumonia—Irinotecan—colon cancer	0.00268	0.00671	CcSEcCtD
Nilutamide—Blood alkaline phosphatase increased—Capecitabine—colon cancer	0.00266	0.00666	CcSEcCtD
Nilutamide—Upper respiratory tract infection—Fluorouracil—colon cancer	0.00266	0.00666	CcSEcCtD
Nilutamide—CYP2C19—liver—colon cancer	0.00263	0.0192	CbGeAlD
Nilutamide—Sweating—Vincristine—colon cancer	0.00262	0.00656	CcSEcCtD
Nilutamide—Pneumonia—Fluorouracil—colon cancer	0.00256	0.00642	CcSEcCtD
Nilutamide—Sweating—Irinotecan—colon cancer	0.00255	0.00639	CcSEcCtD
Nilutamide—Libido decreased—Capecitabine—colon cancer	0.00249	0.00625	CcSEcCtD
Nilutamide—Urinary tract infection—Fluorouracil—colon cancer	0.00248	0.00621	CcSEcCtD
Nilutamide—Hot flush—Capecitabine—colon cancer	0.00247	0.00619	CcSEcCtD
Nilutamide—Menopausal symptoms—Capecitabine—colon cancer	0.00245	0.00614	CcSEcCtD
Nilutamide—Hypoaesthesia—Vincristine—colon cancer	0.00244	0.00612	CcSEcCtD
Nilutamide—Urinary tract disorder—Vincristine—colon cancer	0.00242	0.00607	CcSEcCtD
Nilutamide—Urethral disorder—Vincristine—colon cancer	0.0024	0.00603	CcSEcCtD
Nilutamide—Rhinitis—Irinotecan—colon cancer	0.00239	0.006	CcSEcCtD
Nilutamide—Arthritis—Capecitabine—colon cancer	0.00238	0.00596	CcSEcCtD
Nilutamide—Cardiac failure—Capecitabine—colon cancer	0.00237	0.00593	CcSEcCtD
Nilutamide—Melaena—Methotrexate—colon cancer	0.00231	0.0058	CcSEcCtD
Nilutamide—Gastrointestinal haemorrhage—Capecitabine—colon cancer	0.00231	0.00579	CcSEcCtD
Nilutamide—Visual impairment—Irinotecan—colon cancer	0.0023	0.00577	CcSEcCtD
Nilutamide—CYP2C8—liver—colon cancer	0.0023	0.0168	CbGeAlD
Nilutamide—Rhinitis—Fluorouracil—colon cancer	0.00229	0.00575	CcSEcCtD
Nilutamide—Disturbance in sexual arousal—Capecitabine—colon cancer	0.00229	0.00575	CcSEcCtD
Nilutamide—Hypoaesthesia—Fluorouracil—colon cancer	0.00228	0.0057	CcSEcCtD
Nilutamide—AR—lymph node—colon cancer	0.00218	0.0159	CbGeAlD
Nilutamide—Alopecia—Vincristine—colon cancer	0.00217	0.00543	CcSEcCtD
Nilutamide—Blood creatinine increased—Capecitabine—colon cancer	0.00216	0.00543	CcSEcCtD
Nilutamide—Gynaecomastia—Methotrexate—colon cancer	0.00212	0.00531	CcSEcCtD
Nilutamide—Dry skin—Capecitabine—colon cancer	0.00212	0.00531	CcSEcCtD
Nilutamide—Alopecia—Irinotecan—colon cancer	0.00211	0.00529	CcSEcCtD
Nilutamide—Aspartate aminotransferase increased—Capecitabine—colon cancer	0.00208	0.00522	CcSEcCtD
Nilutamide—Back pain—Vincristine—colon cancer	0.00206	0.00518	CcSEcCtD
Nilutamide—AR—Integrated Breast Cancer Pathway—RAD54L—colon cancer	0.00205	0.048	CbGpPWpGaD
Nilutamide—CYP2C9—liver—colon cancer	0.00204	0.0149	CbGeAlD
Nilutamide—Alanine aminotransferase increased—Capecitabine—colon cancer	0.00204	0.00511	CcSEcCtD
Nilutamide—Alopecia—Fluorouracil—colon cancer	0.00202	0.00507	CcSEcCtD
Nilutamide—Back pain—Irinotecan—colon cancer	0.00201	0.00504	CcSEcCtD
Nilutamide—Influenza—Capecitabine—colon cancer	0.002	0.00501	CcSEcCtD
Nilutamide—Anaemia—Vincristine—colon cancer	0.00197	0.00495	CcSEcCtD
Nilutamide—Angina pectoris—Capecitabine—colon cancer	0.00194	0.00488	CcSEcCtD
Nilutamide—Ill-defined disorder—Irinotecan—colon cancer	0.00193	0.00483	CcSEcCtD
Nilutamide—Anaemia—Irinotecan—colon cancer	0.00192	0.00482	CcSEcCtD
Nilutamide—Leukopenia—Vincristine—colon cancer	0.00191	0.00479	CcSEcCtD
Nilutamide—Malaise—Irinotecan—colon cancer	0.00187	0.0047	CcSEcCtD
Nilutamide—Syncope—Irinotecan—colon cancer	0.00186	0.00467	CcSEcCtD
Nilutamide—Leukopenia—Irinotecan—colon cancer	0.00186	0.00466	CcSEcCtD
Nilutamide—Upper respiratory tract infection—Capecitabine—colon cancer	0.00186	0.00465	CcSEcCtD
Nilutamide—Hypertension—Vincristine—colon cancer	0.00184	0.00462	CcSEcCtD
Nilutamide—Anaemia—Fluorouracil—colon cancer	0.00184	0.00461	CcSEcCtD
Nilutamide—Loss of consciousness—Irinotecan—colon cancer	0.00183	0.00458	CcSEcCtD
Nilutamide—Visual disturbance—Methotrexate—colon cancer	0.00181	0.00455	CcSEcCtD
Nilutamide—Cough—Irinotecan—colon cancer	0.00181	0.00455	CcSEcCtD
Nilutamide—Weight decreased—Capecitabine—colon cancer	0.00181	0.00453	CcSEcCtD
Nilutamide—Hyperglycaemia—Capecitabine—colon cancer	0.0018	0.00452	CcSEcCtD
Nilutamide—Hypertension—Irinotecan—colon cancer	0.00179	0.0045	CcSEcCtD
Nilutamide—Pneumonia—Capecitabine—colon cancer	0.00179	0.00449	CcSEcCtD
Nilutamide—Leukopenia—Fluorouracil—colon cancer	0.00178	0.00447	CcSEcCtD
Nilutamide—Depression—Capecitabine—colon cancer	0.00177	0.00445	CcSEcCtD
Nilutamide—Discomfort—Irinotecan—colon cancer	0.00175	0.00438	CcSEcCtD
Nilutamide—Oedema—Vincristine—colon cancer	0.00174	0.00437	CcSEcCtD
Nilutamide—Urinary tract infection—Capecitabine—colon cancer	0.00173	0.00434	CcSEcCtD
Nilutamide—Haematuria—Capecitabine—colon cancer	0.0017	0.00426	CcSEcCtD
Nilutamide—Oedema—Irinotecan—colon cancer	0.0017	0.00425	CcSEcCtD
Nilutamide—Chest pain—Fluorouracil—colon cancer	0.00169	0.00425	CcSEcCtD
Nilutamide—Hyperhidrosis—Vincristine—colon cancer	0.00168	0.00422	CcSEcCtD
Nilutamide—Discomfort—Fluorouracil—colon cancer	0.00167	0.0042	CcSEcCtD
Nilutamide—Shock—Irinotecan—colon cancer	0.00167	0.00418	CcSEcCtD
Nilutamide—Anorexia—Vincristine—colon cancer	0.00166	0.00416	CcSEcCtD
Nilutamide—Hyperhidrosis—Irinotecan—colon cancer	0.00164	0.00411	CcSEcCtD
Nilutamide—Oedema—Fluorouracil—colon cancer	0.00162	0.00407	CcSEcCtD
Nilutamide—Anorexia—Irinotecan—colon cancer	0.00162	0.00405	CcSEcCtD
Nilutamide—Rhinitis—Capecitabine—colon cancer	0.0016	0.00402	CcSEcCtD
Nilutamide—Hypoaesthesia—Capecitabine—colon cancer	0.00159	0.00399	CcSEcCtD
Nilutamide—AR—Nuclear Receptors—HNF4A—colon cancer	0.00158	0.0371	CbGpPWpGaD
Nilutamide—Urinary tract disorder—Capecitabine—colon cancer	0.00158	0.00396	CcSEcCtD
Nilutamide—Insomnia—Vincristine—colon cancer	0.00158	0.00395	CcSEcCtD
Nilutamide—Oedema peripheral—Capecitabine—colon cancer	0.00157	0.00395	CcSEcCtD
Nilutamide—Urethral disorder—Capecitabine—colon cancer	0.00157	0.00393	CcSEcCtD
Nilutamide—Paraesthesia—Vincristine—colon cancer	0.00156	0.00392	CcSEcCtD
Nilutamide—Anorexia—Fluorouracil—colon cancer	0.00155	0.00388	CcSEcCtD
Nilutamide—Visual impairment—Capecitabine—colon cancer	0.00154	0.00386	CcSEcCtD
Nilutamide—Insomnia—Irinotecan—colon cancer	0.00153	0.00385	CcSEcCtD
Nilutamide—Paraesthesia—Irinotecan—colon cancer	0.00152	0.00382	CcSEcCtD
Nilutamide—Decreased appetite—Vincristine—colon cancer	0.00151	0.0038	CcSEcCtD
Nilutamide—Dyspnoea—Irinotecan—colon cancer	0.00151	0.00379	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Vincristine—colon cancer	0.0015	0.00377	CcSEcCtD
Nilutamide—Dyspepsia—Irinotecan—colon cancer	0.00149	0.00374	CcSEcCtD
Nilutamide—Pain—Vincristine—colon cancer	0.00149	0.00373	CcSEcCtD
Nilutamide—Constipation—Vincristine—colon cancer	0.00149	0.00373	CcSEcCtD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—AXIN2—colon cancer	0.00148	0.0347	CbGpPWpGaD
Nilutamide—Decreased appetite—Irinotecan—colon cancer	0.00147	0.0037	CcSEcCtD
Nilutamide—Insomnia—Fluorouracil—colon cancer	0.00147	0.00368	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Irinotecan—colon cancer	0.00146	0.00367	CcSEcCtD
Nilutamide—Paraesthesia—Fluorouracil—colon cancer	0.00146	0.00366	CcSEcCtD
Nilutamide—Constipation—Irinotecan—colon cancer	0.00145	0.00364	CcSEcCtD
Nilutamide—Pain—Irinotecan—colon cancer	0.00145	0.00364	CcSEcCtD
Nilutamide—Dyspnoea—Fluorouracil—colon cancer	0.00145	0.00363	CcSEcCtD
Nilutamide—Dyspepsia—Fluorouracil—colon cancer	0.00143	0.00359	CcSEcCtD
Nilutamide—Gastrointestinal pain—Vincristine—colon cancer	0.00142	0.00357	CcSEcCtD
Nilutamide—Decreased appetite—Fluorouracil—colon cancer	0.00141	0.00354	CcSEcCtD
Nilutamide—Alopecia—Capecitabine—colon cancer	0.00141	0.00354	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Fluorouracil—colon cancer	0.0014	0.00352	CcSEcCtD
Nilutamide—Feeling abnormal—Irinotecan—colon cancer	0.0014	0.0035	CcSEcCtD
Nilutamide—Pain—Fluorouracil—colon cancer	0.00139	0.00348	CcSEcCtD
Nilutamide—Gastrointestinal pain—Irinotecan—colon cancer	0.00139	0.00348	CcSEcCtD
Nilutamide—Upper respiratory tract infection—Methotrexate—colon cancer	0.00138	0.00346	CcSEcCtD
Nilutamide—Abdominal pain—Vincristine—colon cancer	0.00138	0.00345	CcSEcCtD
Nilutamide—Body temperature increased—Vincristine—colon cancer	0.00138	0.00345	CcSEcCtD
Nilutamide—Erectile dysfunction—Methotrexate—colon cancer	0.00137	0.00343	CcSEcCtD
Nilutamide—Back pain—Capecitabine—colon cancer	0.00135	0.00337	CcSEcCtD
Nilutamide—Abdominal pain—Irinotecan—colon cancer	0.00134	0.00336	CcSEcCtD
Nilutamide—Body temperature increased—Irinotecan—colon cancer	0.00134	0.00336	CcSEcCtD
Nilutamide—Feeling abnormal—Fluorouracil—colon cancer	0.00134	0.00336	CcSEcCtD
Nilutamide—Pneumonia—Methotrexate—colon cancer	0.00133	0.00334	CcSEcCtD
Nilutamide—Depression—Methotrexate—colon cancer	0.00132	0.00331	CcSEcCtD
Nilutamide—Ill-defined disorder—Capecitabine—colon cancer	0.00129	0.00324	CcSEcCtD
Nilutamide—Anaemia—Capecitabine—colon cancer	0.00129	0.00322	CcSEcCtD
Nilutamide—Body temperature increased—Fluorouracil—colon cancer	0.00128	0.00322	CcSEcCtD
Nilutamide—Sweating—Methotrexate—colon cancer	0.00127	0.00319	CcSEcCtD
Nilutamide—Haematuria—Methotrexate—colon cancer	0.00126	0.00317	CcSEcCtD
Nilutamide—Malaise—Capecitabine—colon cancer	0.00125	0.00315	CcSEcCtD
Nilutamide—AR—Nuclear Receptor transcription pathway—HNF4A—colon cancer	0.00125	0.0293	CbGpPWpGaD
Nilutamide—Asthenia—Vincristine—colon cancer	0.00125	0.00313	CcSEcCtD
Nilutamide—Syncope—Capecitabine—colon cancer	0.00125	0.00313	CcSEcCtD
Nilutamide—Leukopenia—Capecitabine—colon cancer	0.00125	0.00312	CcSEcCtD
Nilutamide—AR—Integrated Breast Cancer Pathway—ODC1—colon cancer	0.00124	0.0291	CbGpPWpGaD
Nilutamide—Loss of consciousness—Capecitabine—colon cancer	0.00122	0.00307	CcSEcCtD
Nilutamide—Asthenia—Irinotecan—colon cancer	0.00122	0.00305	CcSEcCtD
Nilutamide—Cough—Capecitabine—colon cancer	0.00121	0.00304	CcSEcCtD
Nilutamide—Hypertension—Capecitabine—colon cancer	0.0012	0.00301	CcSEcCtD
Nilutamide—Diarrhoea—Vincristine—colon cancer	0.00119	0.00299	CcSEcCtD
Nilutamide—Chest pain—Capecitabine—colon cancer	0.00118	0.00297	CcSEcCtD
Nilutamide—Urinary tract disorder—Methotrexate—colon cancer	0.00117	0.00295	CcSEcCtD
Nilutamide—Discomfort—Capecitabine—colon cancer	0.00117	0.00293	CcSEcCtD
Nilutamide—Urethral disorder—Methotrexate—colon cancer	0.00117	0.00292	CcSEcCtD
Nilutamide—Diarrhoea—Irinotecan—colon cancer	0.00116	0.00291	CcSEcCtD
Nilutamide—Dry mouth—Capecitabine—colon cancer	0.00116	0.0029	CcSEcCtD
Nilutamide—Dizziness—Vincristine—colon cancer	0.00115	0.00289	CcSEcCtD
Nilutamide—Pruritus—Fluorouracil—colon cancer	0.00115	0.00288	CcSEcCtD
Nilutamide—Visual impairment—Methotrexate—colon cancer	0.00115	0.00287	CcSEcCtD
Nilutamide—Oedema—Capecitabine—colon cancer	0.00114	0.00285	CcSEcCtD
Nilutamide—CYP2C8—Metapathway biotransformation—CHST4—colon cancer	0.00112	0.0263	CbGpPWpGaD
Nilutamide—Dizziness—Irinotecan—colon cancer	0.00112	0.00281	CcSEcCtD
Nilutamide—Shock—Capecitabine—colon cancer	0.00112	0.0028	CcSEcCtD
Nilutamide—Diarrhoea—Fluorouracil—colon cancer	0.00111	0.00279	CcSEcCtD
Nilutamide—Vomiting—Vincristine—colon cancer	0.00111	0.00278	CcSEcCtD
Nilutamide—Rash—Vincristine—colon cancer	0.0011	0.00275	CcSEcCtD
Nilutamide—Hyperhidrosis—Capecitabine—colon cancer	0.0011	0.00275	CcSEcCtD
Nilutamide—Dermatitis—Vincristine—colon cancer	0.0011	0.00275	CcSEcCtD
Nilutamide—Headache—Vincristine—colon cancer	0.00109	0.00274	CcSEcCtD
Nilutamide—Anorexia—Capecitabine—colon cancer	0.00108	0.00271	CcSEcCtD
Nilutamide—Vomiting—Irinotecan—colon cancer	0.00108	0.0027	CcSEcCtD
Nilutamide—Dizziness—Fluorouracil—colon cancer	0.00107	0.00269	CcSEcCtD
Nilutamide—Rash—Irinotecan—colon cancer	0.00107	0.00268	CcSEcCtD
Nilutamide—Dermatitis—Irinotecan—colon cancer	0.00107	0.00268	CcSEcCtD
Nilutamide—Headache—Irinotecan—colon cancer	0.00106	0.00266	CcSEcCtD
Nilutamide—Alopecia—Methotrexate—colon cancer	0.00105	0.00264	CcSEcCtD
Nilutamide—Nausea—Vincristine—colon cancer	0.00103	0.00259	CcSEcCtD
Nilutamide—Vomiting—Fluorouracil—colon cancer	0.00103	0.00259	CcSEcCtD
Nilutamide—Insomnia—Capecitabine—colon cancer	0.00103	0.00257	CcSEcCtD
Nilutamide—Rash—Fluorouracil—colon cancer	0.00102	0.00257	CcSEcCtD
Nilutamide—Dermatitis—Fluorouracil—colon cancer	0.00102	0.00257	CcSEcCtD
Nilutamide—Paraesthesia—Capecitabine—colon cancer	0.00102	0.00256	CcSEcCtD
Nilutamide—Headache—Fluorouracil—colon cancer	0.00102	0.00255	CcSEcCtD
Nilutamide—Dyspnoea—Capecitabine—colon cancer	0.00101	0.00254	CcSEcCtD
Nilutamide—Nausea—Irinotecan—colon cancer	0.00101	0.00253	CcSEcCtD
Nilutamide—CYP2C19—Metapathway biotransformation—CHST4—colon cancer	0.001	0.0235	CbGpPWpGaD
Nilutamide—Back pain—Methotrexate—colon cancer	0.001	0.00251	CcSEcCtD
Nilutamide—Dyspepsia—Capecitabine—colon cancer	0.000999	0.00251	CcSEcCtD
Nilutamide—Decreased appetite—Capecitabine—colon cancer	0.000987	0.00247	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Capecitabine—colon cancer	0.00098	0.00246	CcSEcCtD
Nilutamide—Pain—Capecitabine—colon cancer	0.000971	0.00243	CcSEcCtD
Nilutamide—Constipation—Capecitabine—colon cancer	0.000971	0.00243	CcSEcCtD
Nilutamide—Nausea—Fluorouracil—colon cancer	0.000965	0.00242	CcSEcCtD
Nilutamide—Ill-defined disorder—Methotrexate—colon cancer	0.000961	0.00241	CcSEcCtD
Nilutamide—Anaemia—Methotrexate—colon cancer	0.000957	0.0024	CcSEcCtD
Nilutamide—Feeling abnormal—Capecitabine—colon cancer	0.000936	0.00235	CcSEcCtD
Nilutamide—Malaise—Methotrexate—colon cancer	0.000934	0.00234	CcSEcCtD
Nilutamide—Gastrointestinal pain—Capecitabine—colon cancer	0.000928	0.00233	CcSEcCtD
Nilutamide—Leukopenia—Methotrexate—colon cancer	0.000927	0.00232	CcSEcCtD
Nilutamide—CYP2C9—Metapathway biotransformation—CHST4—colon cancer	0.000915	0.0214	CbGpPWpGaD
Nilutamide—Cough—Methotrexate—colon cancer	0.000904	0.00227	CcSEcCtD
Nilutamide—Body temperature increased—Capecitabine—colon cancer	0.000897	0.00225	CcSEcCtD
Nilutamide—Abdominal pain—Capecitabine—colon cancer	0.000897	0.00225	CcSEcCtD
Nilutamide—Chest pain—Methotrexate—colon cancer	0.000882	0.00221	CcSEcCtD
Nilutamide—Discomfort—Methotrexate—colon cancer	0.000871	0.00218	CcSEcCtD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—HNF4A—colon cancer	0.000865	0.0203	CbGpPWpGaD
Nilutamide—Hyperhidrosis—Methotrexate—colon cancer	0.000817	0.00205	CcSEcCtD
Nilutamide—Asthenia—Capecitabine—colon cancer	0.000815	0.00204	CcSEcCtD
Nilutamide—Anorexia—Methotrexate—colon cancer	0.000806	0.00202	CcSEcCtD
Nilutamide—Pruritus—Capecitabine—colon cancer	0.000803	0.00201	CcSEcCtD
Nilutamide—Diarrhoea—Capecitabine—colon cancer	0.000777	0.00195	CcSEcCtD
Nilutamide—Insomnia—Methotrexate—colon cancer	0.000764	0.00192	CcSEcCtD
Nilutamide—Paraesthesia—Methotrexate—colon cancer	0.000759	0.0019	CcSEcCtD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—TOP1—colon cancer	0.000758	0.0178	CbGpPWpGaD
Nilutamide—Dyspnoea—Methotrexate—colon cancer	0.000754	0.00189	CcSEcCtD
Nilutamide—Dizziness—Capecitabine—colon cancer	0.000751	0.00188	CcSEcCtD
Nilutamide—Dyspepsia—Methotrexate—colon cancer	0.000744	0.00187	CcSEcCtD
Nilutamide—Decreased appetite—Methotrexate—colon cancer	0.000735	0.00184	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Methotrexate—colon cancer	0.00073	0.00183	CcSEcCtD
Nilutamide—Pain—Methotrexate—colon cancer	0.000723	0.00181	CcSEcCtD
Nilutamide—Vomiting—Capecitabine—colon cancer	0.000722	0.00181	CcSEcCtD
Nilutamide—Rash—Capecitabine—colon cancer	0.000716	0.00179	CcSEcCtD
Nilutamide—Dermatitis—Capecitabine—colon cancer	0.000715	0.00179	CcSEcCtD
Nilutamide—Headache—Capecitabine—colon cancer	0.000711	0.00178	CcSEcCtD
Nilutamide—Feeling abnormal—Methotrexate—colon cancer	0.000696	0.00175	CcSEcCtD
Nilutamide—Gastrointestinal pain—Methotrexate—colon cancer	0.000691	0.00173	CcSEcCtD
Nilutamide—AR—Nuclear Receptors—PPARG—colon cancer	0.000688	0.0161	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—MSH6—colon cancer	0.000676	0.0158	CbGpPWpGaD
Nilutamide—Nausea—Capecitabine—colon cancer	0.000674	0.00169	CcSEcCtD
Nilutamide—Body temperature increased—Methotrexate—colon cancer	0.000668	0.00168	CcSEcCtD
Nilutamide—Abdominal pain—Methotrexate—colon cancer	0.000668	0.00168	CcSEcCtD
Nilutamide—Asthenia—Methotrexate—colon cancer	0.000606	0.00152	CcSEcCtD
Nilutamide—Pruritus—Methotrexate—colon cancer	0.000598	0.0015	CcSEcCtD
Nilutamide—Diarrhoea—Methotrexate—colon cancer	0.000578	0.00145	CcSEcCtD
Nilutamide—Dizziness—Methotrexate—colon cancer	0.000559	0.0014	CcSEcCtD
Nilutamide—AR—Integrated Breast Cancer Pathway—MSH2—colon cancer	0.000548	0.0128	CbGpPWpGaD
Nilutamide—AR—Nuclear Receptor transcription pathway—PPARG—colon cancer	0.000544	0.0127	CbGpPWpGaD
Nilutamide—Vomiting—Methotrexate—colon cancer	0.000537	0.00135	CcSEcCtD
Nilutamide—Rash—Methotrexate—colon cancer	0.000533	0.00134	CcSEcCtD
Nilutamide—Dermatitis—Methotrexate—colon cancer	0.000532	0.00133	CcSEcCtD
Nilutamide—Headache—Methotrexate—colon cancer	0.000529	0.00133	CcSEcCtD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—DCC—colon cancer	0.000517	0.0121	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—CHST5—colon cancer	0.000516	0.0121	CbGpPWpGaD
Nilutamide—AR—Nongenotropic Androgen signaling—SRC—colon cancer	0.000515	0.0121	CbGpPWpGaD
Nilutamide—Nausea—Methotrexate—colon cancer	0.000502	0.00126	CcSEcCtD
Nilutamide—CYP2C19—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.000474	0.0111	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—CHST5—colon cancer	0.000461	0.0108	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—HNF4A—colon cancer	0.000435	0.0102	CbGpPWpGaD
Nilutamide—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.000432	0.0101	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—CHST5—colon cancer	0.00042	0.00984	CbGpPWpGaD
Nilutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	0.000412	0.00965	CbGpPWpGaD
Nilutamide—AR—FOXA1 transcription factor network—EP300—colon cancer	0.0004	0.00938	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—APC—colon cancer	0.000393	0.00921	CbGpPWpGaD
Nilutamide—AR—Nongenotropic Androgen signaling—PIK3CA—colon cancer	0.000392	0.00918	CbGpPWpGaD
Nilutamide—AR—Notch-mediated HES/HEY network—EP300—colon cancer	0.00038	0.0089	CbGpPWpGaD
Nilutamide—AR—Nongenotropic Androgen signaling—HRAS—colon cancer	0.000363	0.0085	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CDH1—colon cancer	0.000362	0.00848	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	0.000348	0.00816	CbGpPWpGaD
Nilutamide—AR—Regulation of Androgen receptor activity—EP300—colon cancer	0.000345	0.00808	CbGpPWpGaD
Nilutamide—AR—Regulation of Androgen receptor activity—SRC—colon cancer	0.000335	0.00786	CbGpPWpGaD
Nilutamide—AR—Coregulation of Androgen receptor activity—CCND1—colon cancer	0.000335	0.00785	CbGpPWpGaD
Nilutamide—AR—Coregulation of Androgen receptor activity—CTNNB1—colon cancer	0.000332	0.00777	CbGpPWpGaD
Nilutamide—AR—Nongenotropic Androgen signaling—AKT1—colon cancer	0.00032	0.0075	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—BAX—colon cancer	0.00031	0.00727	CbGpPWpGaD
Nilutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.000286	0.00671	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—ABCB1—colon cancer	0.000272	0.00637	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—colon cancer	0.00027	0.00632	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CTNNB1—colon cancer	0.000267	0.00626	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	0.000267	0.00625	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—CDKN1A—colon cancer	0.000258	0.00605	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	0.000257	0.00602	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—EP300—colon cancer	0.000248	0.00582	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—CCND1—colon cancer	0.000248	0.0058	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—EP300—colon cancer	0.000246	0.00576	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—CTNNB1—colon cancer	0.000245	0.00574	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—CDKN1A—colon cancer	0.000239	0.00561	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—EP300—colon cancer	0.000228	0.00534	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—BRAF—colon cancer	0.000222	0.00521	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—SRC—colon cancer	0.000222	0.00519	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—CDH1—colon cancer	0.000218	0.0051	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—HNF4A—colon cancer	0.000216	0.00507	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—colon cancer	0.000216	0.00507	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—MYC—colon cancer	0.000214	0.00502	CbGpPWpGaD
Nilutamide—CYP2C8—Arachidonic acid metabolism—PTGS2—colon cancer	0.000203	0.00476	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—APC—colon cancer	0.000196	0.00459	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—EGFR—colon cancer	0.000194	0.00455	CbGpPWpGaD
Nilutamide—AR—Coregulation of Androgen receptor activity—AKT1—colon cancer	0.000186	0.00437	CbGpPWpGaD
Nilutamide—CYP2C19—Arachidonic acid metabolism—PTGS2—colon cancer	0.000181	0.00425	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—CASP3—colon cancer	0.000167	0.0039	CbGpPWpGaD
Nilutamide—CYP2C9—Arachidonic acid metabolism—PTGS2—colon cancer	0.000165	0.00388	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—CASP3—colon cancer	0.000162	0.0038	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—CCND1—colon cancer	0.000162	0.0038	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—CTNNB1—colon cancer	0.000161	0.00376	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—CTNNB1—colon cancer	0.000156	0.00367	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—EP300—colon cancer	0.000149	0.0035	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	0.000149	0.00349	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—AKT1—colon cancer	0.000148	0.00348	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CA7—colon cancer	0.000148	0.00346	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—EP300—colon cancer	0.000145	0.00341	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—VEGFA—colon cancer	0.000141	0.00331	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	0.000138	0.00324	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—VEGFA—colon cancer	0.000138	0.00323	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—AKT1—colon cancer	0.000138	0.00323	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	0.000134	0.00315	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	0.000133	0.00312	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CA7—colon cancer	0.000132	0.00309	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—MYC—colon cancer	0.00013	0.00305	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	0.00013	0.00305	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—EGFR—colon cancer	0.000127	0.00298	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	0.000124	0.0029	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	0.00012	0.00282	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—KRAS—colon cancer	0.00012	0.00282	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CA7—colon cancer	0.00012	0.00282	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	0.000117	0.00275	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	0.000108	0.00253	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	0.000108	0.00252	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—TP53—colon cancer	0.000107	0.0025	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	0.000105	0.00247	CbGpPWpGaD
Nilutamide—AR—Gene Expression—HNF4A—colon cancer	0.000104	0.00244	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	9.96e-05	0.00233	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—PPARG—colon cancer	9.39e-05	0.0022	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	9.15e-05	0.00214	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—AKT1—colon cancer	9.02e-05	0.00211	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CHST5—colon cancer	8.95e-05	0.0021	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—ODC1—colon cancer	8.95e-05	0.0021	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	8.85e-05	0.00207	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—ODC1—colon cancer	7.99e-05	0.00187	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CHST5—colon cancer	7.99e-05	0.00187	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	7.47e-05	0.00175	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CHST5—colon cancer	7.28e-05	0.00171	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—ODC1—colon cancer	7.28e-05	0.00171	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—MYC—colon cancer	5.35e-05	0.00125	CbGpPWpGaD
Nilutamide—AR—Gene Expression—PPARG—colon cancer	4.52e-05	0.00106	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—colon cancer	3.69e-05	0.000866	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—colon cancer	3.3e-05	0.000773	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—colon cancer	3.01e-05	0.000704	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	2.91e-05	0.000681	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	2.59e-05	0.000608	CbGpPWpGaD
Nilutamide—AR—Gene Expression—MYC—colon cancer	2.58e-05	0.000604	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—EP300—colon cancer	2.42e-05	0.000566	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	2.36e-05	0.000554	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—ABCB1—colon cancer	2.36e-05	0.000554	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—TYMS—colon cancer	2.32e-05	0.000544	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—colon cancer	2.16e-05	0.000505	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—ABCB1—colon cancer	2.11e-05	0.000495	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—TYMS—colon cancer	2.07e-05	0.000486	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.97e-05	0.000461	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—ABCB1—colon cancer	1.92e-05	0.000451	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—TYMS—colon cancer	1.89e-05	0.000443	CbGpPWpGaD
Nilutamide—AR—Gene Expression—AKT1—colon cancer	1.79e-05	0.000419	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.79e-05	0.000419	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PPARG—colon cancer	1.64e-05	0.000385	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.6e-05	0.000374	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PPARG—colon cancer	1.47e-05	0.000344	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.45e-05	0.000341	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PPARG—colon cancer	1.34e-05	0.000314	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PTGS2—colon cancer	1.29e-05	0.000303	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PTGS2—colon cancer	1.15e-05	0.000271	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—EP300—colon cancer	1.08e-05	0.000252	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PTGS2—colon cancer	1.05e-05	0.000247	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—EP300—colon cancer	9.61e-06	0.000225	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—EP300—colon cancer	8.76e-06	0.000205	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PIK3CA—colon cancer	7.96e-06	0.000187	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PIK3CA—colon cancer	7.11e-06	0.000167	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—AKT1—colon cancer	6.5e-06	0.000152	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PIK3CA—colon cancer	6.48e-06	0.000152	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—AKT1—colon cancer	5.8e-06	0.000136	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—AKT1—colon cancer	5.29e-06	0.000124	CbGpPWpGaD
